Abstract
Clinical fracture incidence in metastatic hormone-sensitive prostate cancer and risk-reduction following addition of zoledronic acid to androgen deprivation therapy with or without docetaxel: Long-term results from the STAMPEDE trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have